RxDoctor Payments Data

Vikram Kapur, MD

Internal Medicine · Avondale, AZNPI 1063466647

Payments from drug & device makers

$7,977in general payments, 2019–2025

Across 416 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$834
  • Novo Nordisk$603
  • Boehringer Ingelheim$496
  • Amgen$435
  • Abbott$392
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$7,971100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,977 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$157,514
Medicare patients
233
Services billed
2,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$105,504
JardianceEmpagliflozin48$54,559
FarxigaDapagliflozin Propanediol49$51,642
MounjaroTirzepatide40$48,441
LinzessLinaclotide50$36,524
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$31,263
Tresiba Flextouch U-200Insulin Degludec16$23,485
EliquisApixaban16$22,361
TrulicityDulaglutide23$22,124
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$8,794
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen177$7,590
Oxycodone Hcl349$5,697
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,139
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen144$3,875
Incruse ElliptaUmeclidinium Bromide11$3,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$603$105,50498 claims
Lilly USA, LLCMounjaro, Trulicity$129$70,56463 claims
AstraZenecaFarxiga, Symbicort$1,058$54,79261 claims
Boehringer IngelheimJardiance$496$54,55948 claims
AbbVieLinzess$834$36,52450 claims
GSKTrelegy Ellipta, Incruse Ellipta$375$34,92151 claims
PfizerEliquis$143$22,36116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Avondale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →